July 27, 2018 / 5:05 PM / 20 days ago

FDA declines to approve Insys Therapeutic's opioid painkiller

July 27 (Reuters) - Insys Therapeutics Inc said on Friday the U.S. Food and Drug Administration had declined to approve its opioid painkiller, citing potential safety concerns.

Insys' treatment is an under-the-tongue spray formulation of the opioid buprenorphine that was under review to treat moderate-to-severe pain. (Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below